Constant turnover of arachidonic acid and inhibition of a potassium current in Aplysia giant neurons

Evidence of Active-Forgetting Mechanisms? Blocking Arachidonic Acid Release May Slow Forgetting of Sensitization in Aplysia

Long-term sensitization in Aplysia is accompanied by a persistent up-regulation of mRNA encoding the peptide neurotransmitter Phe-Met-Arg-Phe-amide (FMRFa), a neuromodulator that opposes the expression of sensitization through activation of the arachidonic acid second-messenger pathway. We completed a preregistered test of the hypothesis that FMRFa plays a critical role in the forgetting of sensitization. Aplysia received long-term sensitization training and were then given whole-body injections of vehicle (N = 27), FMRFa (N = 26), or 4-bromophenacylbromide (4-BPB; N = 31), a phospholipase inhibitor that prevents the release of arachidonic acid. FMRFa produced no changes in forgetting. 4-BPB decreased forgetting measured 6 d after training [d s = 0.55 95% CI(0.01, 1.09)], though the estimated effect size is uncertain. Our results provide preliminary evidence that forgetting of sensitization may be a regulated, active process in Aplysia, but could also indicate a role for arachidonic acid in stabilizing the induction of sensitization.

Arachidonic Acid-Derived Bioactive Lipids: Their Role and the Role for Their Inhibitors in Dermatology

Background:

In addition to corticosteroids, there are increasing numbers of anti-inflammatory agents that specifically target bioactive lipids generated from arachidonic acid. Knowledge of the diverse mechanisms of action of these different bioactive lipids holds promise in the therapy of a wide spectrum of cutaneous and systemic disorders.

Objective:

Therapeutic manipulations of these lipid molecules through inhibition, stimulation, or direct replacement have broad physiologic effects. These therapeutic strategies not only modulate inflammation, pain, and hemostatic parameters, they also play a role in cardiac, respiratory, renal, and gastrointestinal function and disease, as well as in angiogenesis and in factors that control cell growth and apoptosis important in carcinogenesis.

Conclusion:

Newer drug discovery methods, including combinatorial chemistry with molecular modeling, have made it possible to develop inhibitors and analogs with increasing specificity and bioactivity and decreasing toxicity. Although the application of these analogs and inhibitors for cutaneous disease is limited today, either as primary agents or adjuvant therapy, these drugs will have a place in our therapeutic regimes of the future. We present a review of the therapeutic agents now available from manipulation of these bioactive lipids, and their role and future in dermatology.

Latency of neuroactivity and optimum period of treatment with evening primrose oil in diabetic rats

The interval between oral intake of evening primrose oil and its effect in peripheral nerves of rats was studied 35 days after induction of streptozotocin diabetes. Myelinated and unmyelinated sensory nerve conduction velocities were measured in the saphenous nerve and motor nerve conduction velocity was measured in the sciatic nerve to assess neuroactivity of primrose oil. The severity of diabetes was assessed by levels of HbA1 and plasma glucose. The diabetic state remained constant between 35 and 70 days post induction. Plasma glucose increased by 133%, and HbA1 by 122% in diabetic rats. Myelinated sensory and motor nerves had conduction deficits of 13 and 16%, respectively, 35 days post induction. Unmyelinated nerves had no conduction deficit until 45 days post induction. Primrose oil did not affect nerve conduction velocity in the first 12 h of its administration, but significantly increased it 24 h later (p < 0.001). Daily treatment with primrose oil caused oscillation of nerve conduction velocity in diabetic rats needing 10 days to stabilise. The latency suggests that neuroactivity of primrose oil may be mediated by its metabolic products synthesised in the body, and not by ready made constituents of the oil.

Arachidonic acid and other unsaturated fatty acids alter membrane potential in PC12 and bovine adrenal chromaffin cells

The action of arachidonic acid and other fatty acids on membrane potential in PC12 and bovine chromaffin cells was investigated using a membrane potential-sensitive fluorescent dye. Arachidonic acid (1-40 microM) provoked dose-dependent membrane hyperpolarization, thereby reducing hyperpolarization induced by the K(+)-selective ionophore valinomycin. Other cis-unsaturated fatty acids, but not lipoxygenase products or the saturated fatty acid palmitic acid, also affected membrane potential. Tetraethylammonium blocked the arachidonic acid-induced hyperpolarization. These data suggest that cis-unsaturated fatty acids alter membrane potential in PC12 and bovine chromaffin cells by modulating K+ conductances. Valinomycin-generated hyperpolarization had no effect on agonist-induced Ca2+ influx into bovine chromaffin cells, whereas preincubation with arachidonic acid and other cis-unsaturated fatty acids blocked Ca2+ influx and secretion. We propose a model where internally generated fatty acids act as a feedback to desensitize the stimulated cell via inhibition of receptor-dependent Ca2+ influx and induction of membrane hyperpolarization.

Neuromodulation

The ability of the nervous system to respond to the environment and to learn depends upon the tuning of neuronal electrical activity, loosely called neuromodulation. The substrates for electrical activity and, therefore, neuromodulation are ion channels which may be either synaptic or extrasynaptic. Neuromodulation is dynamic and most frequently involves neurotransmitters and hormones acting via G-protein-coupled pathways.

Regulation of intracellular free arachidonic acid in Aplysia nervous system

We have studied the regulation of arachidonic acid (AA) uptake, metabolism, and release in Aplysia nervous system. Following uptake of [3H]AA, the distribution of radioactivity in intracellular and extracellular lipid pools was measured as a function of time in the presence or absence of exogenous AA. The greatest amount of AA was esterified into phosphatidylinositol (relative to pool size). We found that the intracellular free AA pool underwent rapid turnover, and that radioactive free AA and eicosanoids were released at a rapid rate into the extracellular medium, both in the presence and absence of exogenous AA. Most of the released radioactivity originated from phosphatidylinositol. Two pharmacological agents were found to modulate AA metabolism in Aplysia ganglia. The phorbol ester, 12-O-tetradecanoylphorbol 13-acetate, stimulated liberation of AA from phosphatidylinositol and phosphatidylcholine. This resulted in an increase in free internal and secreted AA, an increase in conversion of AA to eicosanoids, and an increase in esterification of AA into triacylglycerol. The half maximal dose for TPA-stimulated AA turnover was 15 nM, and the stimulation was dependent on the presence of extracellular calcium. 4-bromophenacylbromide inhibited the redistribution of radioactivity from phospholipid into triacylglycerol, indicating BPB was acting as a phospholipase inhibitor in Aplysia as it does in other systems. These pharmacological agents, in addition to providing information about the regulation of AA metabolism and release, are useful tools for investigating the physiological function of the rapid turnover of AA in Aplysia nervous system.